Advertisement

Leflunomide: Is It the Game Changer in Musculoskeletal Chronic Graft Versus Host Disease?

  • Kalasekhar Vijaysekharan
  • Sachin Punatar
  • Avinash Bonda
  • Aniket Mohite
  • Kartthik Shanmugam
  • Lingaraj Nayak
  • Anant Gokarn
  • Navin Khattry
Correspondence

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research Involving Human Participants

This is not a clinical trial or research project. This is a case report highlighting the use of a drug routinely used in rheumatoid arthritis (an autoimmune disorder). The patient was treated at the discretion of the treating clinician.

References

  1. 1.
    Blazar BR, Murphy WJ, Abedi M (2012) Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 12:443–458CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R et al (2009) Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 114:709–718CrossRefPubMedGoogle Scholar
  3. 3.
    Breedveld FC, Dayer JM (2000) Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59:841–849CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Schorlemmer HU, Bartlett RR, Kurrle R (1997) Analogues of leflunomide’s primary metabolite, the malononitrilamides, prevent the development of graft-versus-host disease. Transpl Proc 29:1298–1301CrossRefGoogle Scholar
  5. 5.
    Mrowka C, Thoenes GH, Langer KH, Bartlett RR (1994) Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomide. Ann Hematol 68:195–199CrossRefPubMedGoogle Scholar
  6. 6.
    Déage V, Burger D, Dayer JM (1998) Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases. Eur Cytokine Netw 9:663–668PubMedGoogle Scholar
  7. 7.
    Bartlett RR, Anagnostopulos H, Zielinski T, Mattar T, Schleyerbach R (1993) Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathol 14:381–394CrossRefPubMedGoogle Scholar
  8. 8.
    Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan A (1996) Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 61:635–642CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  • Kalasekhar Vijaysekharan
    • 1
  • Sachin Punatar
    • 1
  • Avinash Bonda
    • 1
  • Aniket Mohite
    • 1
  • Kartthik Shanmugam
    • 1
  • Lingaraj Nayak
    • 1
  • Anant Gokarn
    • 1
  • Navin Khattry
    • 1
  1. 1.HSCT Unit, Department of Medical OncologyACTREC, Tata Memorial CentreKharghar, Navi MumbaiIndia

Personalised recommendations